The combined use of Rakicidin A plus IM or dasatinib also resulted in synergistic cytotoxic effects on hypoxia-adapted BCR-ABL+ CML cells [56]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.